{"id":"W4403833200","doi":"10.1681/asn.2024r76pk0r1","title":"Efficacy and Safety of Ravulizumab in IgAN: Week 50 Results from a Phase 2 Randomized Controlled Trial","year":2024,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Randomized controlled trial; Medicine; Safety profile; Phase (matter); Internal medicine; Urology; Adverse effect; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003790073,0.00153347,0.002696122,0.0003895442,0.0004506294,0.001273221,0.0008051191,0.002209902,0.006505308],"category_scores_gemma":[0.00260345,0.0006408481,0.002002484,0.0003626725,0.0008536515,0.001097771,0.0004051084,0.002239479,0.001145513],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006902007,"about_ca_system_score_gemma":0.0009124729,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004884145,"about_ca_topic_score_gemma":0.001156514,"domain_scores_codex":[0.9985889,0.0008263257,0.000092788,0.0002193814,0.0001132242,0.0001594801],"domain_scores_gemma":[0.9986134,0.0003791631,0.0004214427,0.000159743,0.00009820703,0.0003280437],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9666865,0.006387933,0.000805492,0.0008136691,0.001199547,0.00005352533,0.00006830374,0.0003326692,0.004806026,0.00006455814,0.00121549,0.01756629],"study_design_scores_gemma":[0.9360456,0.05728221,0.004330978,0.0000737826,0.0005683348,0.00004560042,0.00001415602,0.0003580034,0.0004160604,0.0001028227,0.000744964,0.00001744247],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9787203,0.008357059,0.001348892,0.000804223,0.0003317871,0.005583638,0.001768235,0.0003226579,0.002763195],"genre_scores_gemma":[0.9785787,0.003691198,0.002305602,0.001423121,0.0004186618,0.008575326,0.001648229,0.00006163465,0.003297545],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006505308,"threshold_uncertainty_score":0.02176243,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009869083897193067,"score_gpt":0.267093345491571,"score_spread":0.257224261594378,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}